Intravitreal acetazolamide implant for pseudophakic cystoid macular edema.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY

Documenta Ophthalmologica Pub Date : 2023-08-01 DOI:10.1007/s10633-023-09939-6

Rodrigo Jorge, Isabela Franco Villela, Christian Fernandes, Thais Marino de Azevedo Bastos, Ingrid U Scott, Armando da Silva Cunha, Silvia Ligório Fialho, Pedro Henrique Reis da Silva, André Messias

{"title":"Intravitreal acetazolamide implant for pseudophakic cystoid macular edema.","authors":"Rodrigo Jorge, Isabela Franco Villela, Christian Fernandes, Thais Marino de Azevedo Bastos, Ingrid U Scott, Armando da Silva Cunha, Silvia Ligório Fialho, Pedro Henrique Reis da Silva, André Messias","doi":"10.1007/s10633-023-09939-6","DOIUrl":null,"url":null,"abstract":"Background: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases.Report: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 μg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication.Conclusion: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.","PeriodicalId":11207,"journal":{"name":"Documenta Ophthalmologica","volume":"147 1","pages":"71-75"},"PeriodicalIF":2.6000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Documenta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10633-023-09939-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pseudophakic cystoid macular edema (PCME) is the most common cause of visual acuity deterioration after uncomplicated cataract surgery. There is no consensus regarding how to manage recurrent or refractory cases.

Report: A 54-year-old woman complained of decreased vision and central metamorphopsia in the right eye (OD) 3 months after uneventful cataract surgery. Visual acuity was 0.3 logMAR (20/40) OD and 0.1 logMAR (20/25) OS. Reduced macular brightness was seen OD on funduscopy associated with increased macular thickness on optical coherence tomography (OCT). Pseudophakic cystoid macular edema (PCME) was diagnosed, and treatment with oral acetazolamide was tried without success. The patient underwent a single intravitreal injection of an acetazolamide implant (260 μg) OD as off-label treatment. Four weeks following the injection, she reported complete resolution of her metamorphopsia and visual loss OD. Four months later, her visual acuity was 0.0 logMAR (20/20) in OD and 0.1 logMAR (20/25) in OS. The patient reported no discomfort after the injection procedure. Laboratory and ophthalmologic tests did not identify any adverse effects of the medication.

Conclusion: We show that PCME refractory to conventional treatment improved after intravitreal acetazolamide implant injection. Further investigation is warranted to confirm these preliminary findings.

Abstract Image

查看原文本刊更多论文

玻璃体内植入乙酰唑胺治疗假性晶状体囊样黄斑水肿。

背景:假性晶状体囊样黄斑水肿(PCME)是无并发症白内障手术后视力恶化的最常见原因。关于如何处理复发或难治性病例尚无共识。报告:一名54岁女性在白内障手术后3个月出现右眼视力下降和中央变形。视力为0.3 logMAR (20/40) OD, 0.1 logMAR (20/25) OS。眼底镜显示黄斑亮度降低，光学相干断层扫描(OCT)显示黄斑厚度增加。诊断为假晶状体囊样黄斑水肿(PCME)，口服乙酰唑胺治疗无效。患者接受单次玻璃体内注射乙酰唑胺植入物(260 μg)作为超说明书治疗。注射后四周，她报告她的变形和视力丧失完全消退。4个月后，她的视力在OD组为0.0 logMAR(20/20)，在OS组为0.1 logMAR(20/25)。患者报告注射后无不适。实验室和眼科检查未发现药物有任何不良反应。结论:玻璃体腔内注射乙酰唑胺后PCME难治性得到改善。有必要进一步调查以证实这些初步调查结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Documenta Ophthalmologica 医学-眼科学

CiteScore

3.50

自引率

21.40%

发文量

审稿时长

>12 weeks

期刊介绍： Documenta Ophthalmologica is an official publication of the International Society for Clinical Electrophysiology of Vision. The purpose of the journal is to promote the understanding and application of clinical electrophysiology of vision. Documenta Ophthalmologica will publish reviews, research articles, technical notes, brief reports and case studies which inform the readers about basic and clinical sciences related to visual electrodiagnosis and means to improve diagnosis and clinical management of patients using visual electrophysiology. Studies may involve animals or humans. In either case appropriate care must be taken to follow the Declaration of Helsinki for human subject or appropriate humane standards of animal care (e.g., the ARVO standards on Animal Care and Use).